PLx Pharma

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, PLx Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

PLx Pharma: 9 sponsored US clinical trials, none currently recruiting.

PLx Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastroduodenal Ulceration, with 1 trials.

Top-decile sponsor footprint

PLx Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 4

Pharmacodynamic and Pharmacokinetic Study of PL-ASA

NCT04811625
COMPLETED Phase 1

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

NCT05055752
COMPLETED Phase 3

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
COMPLETED Phase 2

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

NCT01646814
COMPLETED Phase 3

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
COMPLETED Phase 1

Food-Effect Pharmacokinetic Study of PL2200

NCT01244100
COMPLETED Phase 2

Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults

NCT01139190
COMPLETED Phase 1

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

NCT00966641
COMPLETED Phase 1

Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers

NCT00872534

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2
Phase 4 1

Therapeutic Areas

Gastroduodenal Ulceration 1
Bioequivalence 1
Diabetes Mellitus, Type 2 1

How the PLx Pharma early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Gastroduodenal Ulceration (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

PLx Pharma: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

PLx Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share PLx Pharma4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
PLx Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

PLx Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this PLx Pharma page

9 registered trials is a research-attention snapshot, not an endorsement of PLx Pharma or any single study.

  • None of PLx Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gastroduodenal Ulceration is the condition PLx Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastroduodenal Ulceration trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

PLx Pharma pipeline card: 9 registered trials from official public datasets.Report a data error.